ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向和生物制剂安全性的共识文件:感染病学视角(可溶性免疫效应分子[II]:靶向白介素、免疫球蛋白和补体因子的药物)
本共识从感染病学角度综述靶向白介素、免疫球蛋白和补体因子药物的安全性。IL-1或IL-5靶向药物感染风险中等且无特定预防策略推荐;IL-6/IL-6受体靶向药物风险增加与抗TNF-α药物相似;IL-12/23靶向药物似乎不构成有意义的感染风险,但可考虑筛查潜伏结核,HBsAg阳性患者应给予抗病毒预防;IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病;使用IgE靶向药物前应考虑筛查粪类圆线虫等土源性蠕虫;C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须在开始治疗前2-4周接种脑膜炎球菌疫苗并给予化学预防。
要点
- IL-1或IL-5靶向药物感染风险中等,无特定预防策略推荐。
- C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须接种疫苗和化学预防。
- IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病。
核心结论
- IL-1或IL-5靶向药物感染风险中等且无特定预防策略推荐;IL-6/IL-6受体靶向药物风险增加与抗TNF-α药物相似;IL-12/23靶向药物似乎不构成有意义的感染风险;IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病;使用IgE靶向药物前应考虑筛查粪类圆线虫等土源性蠕虫;C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须接种脑膜炎球菌疫苗和化学预防;应特别鼓励采取预防策略以最小化与依库珠单抗相关的奈瑟菌感染。
研究设计与样本
- ESCMID免疫功能受损宿主感染研究组(ESGICH)共识文件,基于计算机MEDLINE检索,检索词为与每种药物或治疗类别相关的MeSH术语。
主要发现
- 接受IL-1靶向药物(阿那白滞素、卡那奴单抗或利纳西普)或IL-5靶向药物(美泊利珠单抗)的患者感染风险中等,无特定预防策略推荐。
- 使用IL-6/IL-6受体靶向药物(托珠单抗和西妥昔单抗)与观察到的抗肿瘤坏死因子-α药物相似的风险增加相关。
- IL-12/23靶向药物(乌司奴单抗)似乎不构成有意义的感染风险,但可考虑筛查潜伏结核感染,乙型肝炎表面抗原阳性患者应给予抗病毒预防。
- IL-17靶向药物(苏金单抗、布罗达鲁单抗和伊克珠单抗)治疗可能导致轻至中度皮肤黏膜念珠菌病。
- 对于来自粪类圆线虫和其他土源性蠕虫流行地区的患者,接受IgE靶向药物(奥马珠单抗)前应考虑筛查粪类圆线虫和其他土源性蠕虫。
关键数值与推荐
- 接受IL-1靶向药物(阿那白滞素、卡那奴单抗或利纳西普)或IL-5靶向药物(美泊利珠单抗)的患者感染风险中等,无特定预防策略推荐。
- 使用IL-6/IL-6受体靶向药物(托珠单抗和西妥昔单抗)与观察到的抗肿瘤坏死因子-α药物相似的风险增加相关。
- IL-12/23靶向药物(乌司奴单抗)似乎不构成有意义的感染风险,但可考虑筛查潜伏结核感染,乙型肝炎表面抗原阳性患者应给予抗病毒预防。
- 使用IL-17靶向药物(苏金单抗、布罗达鲁单抗和伊克珠单抗)可能导致轻至中度皮肤黏膜念珠菌病。
- 对于来自粪类圆线虫和其他土源性蠕虫流行地区的患者,接受IgE靶向药物(奥马珠单抗)前应考虑筛查粪类圆线虫和其他土源性蠕虫。
临床怎么用
- C5靶向药物(依库珠单抗)与荚膜细菌(尤其是奈瑟菌属)感染风险显著增加相关;必须在开始依库珠单抗前2-4周接种脑膜炎球菌疫苗并给予化学预防。
- 有高危行为者及其伴侣应筛查淋球菌感染。
- 应特别鼓励采取预防策略以最小化与依库珠单抗相关的奈瑟菌感染。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection. IMPLICATIONS: Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.
引用
- Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018. PMID: 29447987. doi:10.1016/j.cmi.2018.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。